Navigation Links
Elekta / Mitsubishi Electric Collaboration Helps Japan's Gunma University Heavy Ion Medical Center Launch Advanced Carbon Ion Therapy for Treating Cancer
Date:5/17/2010

GUNMA, Japan and ATLANTA, May 17 /PRNewswire/ -- Three years of teamwork between Elekta and Mitsubishi Electric Corporation came to fruition in March when Gunma University Heavy Ion Medical Center used carbon ion radiotherapy to treat a patient with prostate cancer. Elekta and Mitsubishi Electric worked to facilitate the use of Elekta's treatment planning software, XiO®, for delivery with Mitsubishi Electric's particle beam treatment system.

Compared to proton therapy, carbon ions are heavier and produce a much higher linear energy transfer. Because carbon ions can create a higher energy dose, this type of therapy is designed to be effective in treating select radio-resistant tumors.

Elekta teams in Japan and the United States (St. Louis) worked with Mitsubishi Electric to implement the NIRS (National Institute of Radiological Sciences) new dose calculation engine into Mitsubishi Electric's particle dose calculation server. This server was then interfaced with XiO by both teams.

"The addition of carbon ions to our treatment planning portfolio is a milestone for Elekta," says Roberto Pellegrini, Ph.D., director of treatment planning at Elekta. "It demonstrates our commitment to provide clinicians with the flexibility to integrate state-of-the-art planning capabilities across a wide range of radiation therapy delivery techniques."

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible today.

Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. For more information about Elekta, please visit www.elekta.com.


'/>"/>
SOURCE Elekta
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Barnes-Jewish Hospital to Provide Gamma Knife Surgery to Additional Patient Groups With New Elekta Technology
2. Presbyterian Cancer Center to Offer Cancer Patients High-End VMAT Treatments With the Installation of Elekta Infinity
3. CMS, Inc., an Elekta Company, Announces Commercial Availability of Focal4D(TM)
4. Elekta Sees Record Attendance and Record Number of Submitted Abstracts at International Leksell Gamma Knife(R) Society Meeting in Quebec, Canada
5. Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to Froedtert Hospital in Milwaukee
6. Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to The Nebraska Medical Center
7. Elekta Announces First Volumetric Modulated Arc Therapy Cancer Treatment at Royal Marsden Hospital
8. Elekta Announces First Two Clinical Sites Using VMAT Cancer Treatment Capability
9. Elekta Announces Clinical Start-up of Elekta Synergy(R) S at UPMC
10. Elekta Negotiates To Acquire CMS
11. Elekta Showcases Stereotactic Systems for Cancer Care at Astro 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... (PRWEB) , ... December 01, 2016 , ... ACEA Biosciences, ... its Phase I/II clinical trials for AC0010 at the World Conference on Lung Cancer ... providing an update on the phase I/II clinical trials for AC0010 in patients with ...
(Date:12/2/2016)... ... December 01, 2016 , ... DrugDev believes the only way to ... technology experience. All three tenets were on display at the 2nd Annual DrugDev User ... 40 sponsor, CRO and site organizations to discuss innovation and the future of clinical ...
(Date:12/2/2016)... , December 2, 2016 The ... 2021, growing at a CAGR of 7.3% during the forecast period ... hospitals and diagnostic laboratories segment accounted for the largest share of ... ... report on global immunohistochemistry (IHC) market spread across 225 pages, profiling ...
(Date:11/30/2016)... Nov. 30, 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" ... PBT.U), is excited to announce the formation of ... developing preclinical ophthalmology assets through proof of concept. ... created by Portage Pharmaceuticals Limited and being developed ... surface and anterior segment diseases. This agent has ...
Breaking Biology Technology:
(Date:11/30/2016)... , Nov. 30, 2016 Not many of us realize that we spend ... recovery so we need to do it well. Inadequate sleep levels have been found ... pressure, stroke, diabetes, and even cancer. Maybe now is the best time ... could help them to manage their sleep quality? Continue ... ...
(Date:11/29/2016)... -- BioDirection, a privately held medical device company developing ... of concussion and other traumatic brain injury (TBI), announced ... with the U.S. Food and Drug Administration (FDA) to ... the meeting company representatives reviewed plans for clinical development ... of a planned pilot trial. "We ...
(Date:11/29/2016)... CANNES, France , November 29, 2016 Nearly ... Continue Reading ... ... System is part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric ...
Breaking Biology News(10 mins):